VSA-2 is a recently developed semisynthetic saponin immunostimulant.
It is prepared by incorporating a terminal-functionalized side chain
to the branched trisaccharide domain at the C3 position of Momordica saponin II (MS II) isolated from the seeds
of perennial Momordica cochinchinensis Spreng. Direct comparison of VSA-2 and the clinically proven saponin
adjuvant QS-21 shows that VSA-2 is comparable to QS-21 in enhancing
humoral and cellular immune responses. Structure–activity relationship
studies show that structural changes in the side chain have a significant
impact on saponins’ adjuvant activity. However, with the VSA-2
molecular framework intact, the new VSA-2 analogues with various substitution(s)
at the terminal benzyl group of the side chain retain the ability
of potentiating antigen-specific humoral and cellular responses